Chicago, USA — Recently, the 2026 Heart Rhythm Society Annual Meeting (HRS 2026) concluded successfully in Chicago, USA. Following EHRA 2026, Shanghai MicroPort EP MedTech Co., Ltd. (MicroPort EP) once again made a major international appearance with its "PRIME" suite of five technology platforms, comprehensively showcasing its integrated solution for interventional diagnosis and treatment in electrophysiology and further strengthening the impact of Chinese innovation in the global arrhythmia treatment landscape.

At HRS 2026, MicroPort EP presented its product portfolio in a systematic, matrix-like manner. The five technology pipelines cover key areas including pulsed field ablation, radiofrequency ablation, cryoablation, intracardiac echocardiography, and magnetic robotic navigation, forming a complete solution system with multi-energy synergy.

Within this portfolio, alongside mature products already widely used in clinical practice, several innovative products made their debut at HRS, attracting significant attention and inquiries from many experts. Core highlights included:

PulseMagic™ Pulsed Field Ablation System, supporting both microsecond and nanosecond dual technology pathways, and received EU MDR certification in April this year;

FireMagic™ Radiofrequency Ablation Solution, integrating FireMagic™ contact force monitoring, high-density mapping, and automated mapping technologies, with its high-density mapping catheter receiving EU MDR certification in February this year;

IceMagic™ Cryoablation Catheter with Surface Temperature Monitoring, leveraging surface temperature measurement technology to further enhance procedural safety and efficacy, received EU MDR certification in July last year;

Magbot™ Magnetic Navigation System, enhancing procedural precision and safety while optimizing catheter lab workflow efficiency and strengthening integration of procedural information, with its magnetic navigation catheter receiving EU MDR certification in February this year;

EasyEcho™ Intracardiac Echocardiography Catheter, providing high-definition real-time imaging to support precise intraoperative decision-making.

As a Chinese company capable of providing the Columbus™ 3D Cardiac Electrophysiological Mapping System and a complete solution, MicroPort EP attracted electrophysiology experts from multiple countries including the United States, Germany, Australia, Finland, Brazil, and Argentina to visit, exchange ideas, and experience its technologies during the congress.

During the exhibition, renowned electrophysiology expert Prof. Sabine Ernst visited the booth and engaged in in-depth discussions with the team on the clinical value and technological innovations of magnetic navigation technology in arrhythmia treatment.

Dr. Ayan Abdrakhmanov, President of the Kazakh Heart Rhythm Society, also visited the booth, learning in detail about MicroPort EP's latest advancements in interventional arrhythmia treatment and engaging in thorough discussions on the pulsed field ablation solution. He highly recognized MicroPort EP's innovative progress in the pulsed field ablation field and expressed anticipation for more innovative products to be introduced into clinical practice in the future.

A dedicated Columbus™ experience zone was set up at the booth, where experts could use the PulseMagic™ Spiral Pulsed Field Ablation Catheter to perform mapping-modeling-ablation procedures, immersing themselves in the product's performance.

Experts praised the pressure-sensing pulsed catheter for its precise, real-time contact force visualization, multi-function integration, and customizable energy delivery, noting that these features help physicians improve the efficiency and accuracy of radiofrequency ablation procedures. Multiple experts commented that the catheter, through real-time contact force monitoring and 3D visualization combined with the PFEI quantitative indicator, provides a clear basis for intraoperative decision-making, making ablation strategies more precise and controllable, and effectively enhancing procedural safety and efficacy.

Moving forward, MicroPort EP will actively expand its global presence, continue to deepen the strategic deployment of its all-in-one technology platform, provide patients and physicians with more comprehensive products and professional services, and deliver a globally competitive integrated solution for interventional diagnosis and treatment in electrophysiology.